SEC Form 10-Q Summary
Source discrepancy: The request identifies Palisade Bio, Inc., but the supplied Form 10-Q is for Neuralstem, Inc. The summary below reflects the supplied filing, for the quarterly period ended September 30, 2016.
Business Context and Reporting Period
Neuralstem is a development-stage biotechnology company focused on central nervous system therapies, including the NSI-189 small-molecule program and NSI-566 neural stem-cell therapy. The company reported 11 full-time employees at September 30, 2016 and had no commercially approved products.
The filing covers the three and nine months ended September 30, 2016, compared with the corresponding 2015 periods. Its principal programs included a Phase 2 NSI-189 trial for major depressive disorder and earlier-stage NSI-566 trials for ALS, chronic spinal cord injury and stroke.
Financial Metrics
| Metric | Three months ended September 30, 2016 | Three months ended September 30, 2015 |
|---|---|---|
| Revenue | $2,500 | $2,500 |
| Operating expenses | $4.9 million | $5.2 million |
| Operating loss | $4.9 million | $5.2 million |
| Net loss | $5.2 million | $5.6 million |
| Loss per share | $0.05 | $0.06 |
| Metric | Nine months ended September 30, 2016 | Nine months ended September 30, 2015 |
|---|---|---|
| Revenue | $7,500 | $7,917 |
| Research and development expense | $9.1 million | $9.9 million |
| General and administrative expense | $5.9 million | $4.9 million |
| Operating loss | $15.0 million | $14.8 million |
| Net loss | $15.7 million | $16.1 million |
| Loss per share | $0.15 | $0.18 |
| Cash used in operating activities | $11.5 million | $15.0 million |
- Gross margin and product margins are not meaningful because revenue consisted primarily of small intellectual-property licensing fees; the company generated no revenue from product sales.
- Cash and cash equivalents were $5.7 million at September 30, 2016, compared with $4.7 million at December 31, 2015. Short-term investments declined from $7.5 million to zero as investments matured and were used to fund operations.
- Total assets were $8.5 million, total liabilities were $12.2 million, and stockholders’ deficit was $3.8 million at September 30, 2016.
- Current liabilities were $7.9 million, including $4.8 million of current long-term debt. A $4.4 million derivative liability related to stock warrants was also recorded.
- Net cash provided by investing activities was $7.4 million, primarily from maturities of short-term investments. Financing activities provided $5.1 million, including approximately $8.2 million of net equity proceeds, partly offset by $3.4 million of debt repayments.
- Interest expense was $949,000 for the nine-month period. Share-based compensation was $2.9 million.
Material Changes Versus the Prior Comparable Period
- Third-quarter research and development expense increased 6% to $3.6 million, primarily because of higher clinical-trial spending for the NSI-189 Phase 2 study.
- Third-quarter general and administrative expense decreased 26% to $1.3 million following the May 2016 workforce reduction.
- For the first nine months, research and development expense declined 8%, mainly because of lower NSI-189 manufacturing costs, while general and administrative expense increased 19% because of executive severance and accelerated and newly granted stock compensation.
- Operating cash burn improved by approximately $3.5 million year over year, but remained substantial at $11.5 million.
- Shares outstanding increased materially, from 92.0 million at December 31, 2015 to 114.8 million at September 30, 2016, primarily reflecting 2016 equity financing and equity awards.
- In May 2016, the company raised approximately $8.2 million net through public and private offerings of common stock and warrants. The offerings included 22.7 million warrants with non-standard anti-dilution provisions, recorded as derivative liabilities.
Guidance, Outlook, Risks and Unusual Items
- Management stated that the $5.7 million cash balance was expected to fund operations only through December 2016. The company reported substantial doubt about its ability to continue as a going concern without additional financing.
- In September 2016, the company entered into a definitive agreement with Tianjin Pharmaceutical Holdings Co., Ltd. for a $20 million private placement of common and convertible preferred securities. Closing was expected in the fourth quarter of 2016, but was not assured.
- The company stated that it did not expect to be profitable in the next several years and would require significant additional capital for clinical development, regulatory activities, manufacturing and general operations.
- Approximately $470,000 of costs were recorded for the May 2016 cost-reduction plan, including severance, employee payments and non-cash option modifications. Approximately $17,000 remained payable at September 30, 2016.
- A former executive agreed to reimburse the company approximately $658,000 over six years for expenses the company determined had been improperly paid. The company recorded a $459,000 non-operating gain; the receivable was recorded net of a $199,000 discount.
- On October 18, 2016, Nasdaq staff notified the company of a determination to delist its securities for continued non-compliance with the $1.00 minimum bid-price requirement. The company requested a hearing, which stayed the delisting action pending review.
- The company had approximately $4.95 million of aggregate debt principal outstanding at September 30, 2016. Required debt payments included approximately $435,000 per month through March 2017 and an approximately $2.8 million balloon payment in April 2017. Substantially all assets, including intellectual property, secured the debt.
- Key risks include clinical-trial failure or delay, regulatory non-approval, dependence on third-party manufacturers and clinical organizations, intellectual-property challenges, competition, dilution from future financing, debt default and potential Nasdaq delisting.
Investor Verification Checklist
- Verify the issuer identity: the supplied filing is for Neuralstem, Inc., not Palisade Bio, Inc.
- Confirm whether the $20 million Tianjin financing closed and review the final security terms, including preferred-stock rights and conversion provisions.
- Check subsequent filings for the company’s going-concern status, cash runway and any restructuring, bankruptcy or cessation-of-operations developments.
- Review the debt agreement for payment compliance, covenant status, collateral and the April 2017 balloon obligation.
- Confirm the outcome of the Nasdaq hearing and whether the company remained listed.
- Assess dilution from outstanding options, warrants and convertible securities; approximately 66.8 million shares were reserved for potential issuance at September 30, 2016.
- Verify subsequent clinical results for the NSI-189 Phase 2 trial and the continued status of NSI-566 programs.